Tradewinds Capital Management LLC Has $65,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Tradewinds Capital Management LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 27.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,330 shares of the biopharmaceutical company’s stock after acquiring an additional 500 shares during the quarter. Tradewinds Capital Management LLC’s holdings in Pfizer were worth $65,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. VisionPoint Advisory Group LLC boosted its position in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares during the last quarter. GoalVest Advisory LLC boosted its position in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC acquired a new position in Pfizer during the 4th quarter worth approximately $32,000. Trivant Custom Portfolio Group LLC boosted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Wednesday, June 26th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Finally, Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus price target of $35.54.

Pfizer Stock Performance

PFE stock traded down $0.17 during trading hours on Wednesday, hitting $27.66. 8,189,874 shares of the stock were exchanged, compared to its average volume of 40,386,574. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $156.74 billion, a P/E ratio of -462.33, a P/E/G ratio of 1.10 and a beta of 0.69. The company has a 50-day simple moving average of $27.96 and a two-hundred day simple moving average of $27.71. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter last year, the business earned $1.23 EPS. On average, analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.07%. The ex-dividend date of this dividend is Thursday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.